175 related articles for article (PubMed ID: 11451204)
21. Immunohistochemical markers for prognosis of anaplastic astrocytomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):203-15. PubMed ID: 12187956
[TBL] [Abstract][Full Text] [Related]
22. Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma. Case report.
Macaulay RJ; Jay V; Hoffman HJ; Becker LE
J Neurosurg; 1993 Nov; 79(5):761-8. PubMed ID: 8410257
[TBL] [Abstract][Full Text] [Related]
23. Pediatric Pleomorphic Xanthoastrocytoma: A National Database Inquiry on Current Treatment Approaches in the United States.
Scarpelli DB; Yu Y; Tep AC; Bergue B; Degnin C; Chen Y; McClelland S; Jaboin JJ
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1415. PubMed ID: 33963808
[TBL] [Abstract][Full Text] [Related]
24. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.
Marton E; Feletti A; Orvieto E; Longatti P
J Neurol Sci; 2007 Jan; 252(2):144-53. PubMed ID: 17189643
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
Machen SK; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
[TBL] [Abstract][Full Text] [Related]
26. Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients.
Lee C; Byeon Y; Kim GJ; Jeon J; Hong CK; Kim JH; Kim YH; Cho YH; Hong SH; Chong SJ; Song SW
Sci Rep; 2024 Feb; 14(1):4615. PubMed ID: 38409363
[TBL] [Abstract][Full Text] [Related]
27. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma.
Nakamura M; Konishi N; Tsunoda S; Hiasa Y; Tsuzuki T; Inui T; Sakaki T
Cancer; 1997 Jul; 80(2):242-9. PubMed ID: 9217037
[TBL] [Abstract][Full Text] [Related]
28. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
29. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
30. Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes.
Sallinen PK; Sallinen SL; Helén PT; Rantala IS; Rautiainen E; Helin HJ; Kalimo H; Haapasalo HK
Neuropathol Appl Neurobiol; 2000 Aug; 26(4):319-31. PubMed ID: 10931365
[TBL] [Abstract][Full Text] [Related]
31. Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors.
Powell SZ; Yachnis AT; Rorke LB; Rojiani AM; Eskin TA
Am J Surg Pathol; 1996 Jan; 20(1):80-5. PubMed ID: 8540612
[TBL] [Abstract][Full Text] [Related]
32. Extraventricular neurocytomas: pathologic features and clinical outcome.
Brat DJ; Scheithauer BW; Eberhart CG; Burger PC
Am J Surg Pathol; 2001 Oct; 25(10):1252-60. PubMed ID: 11688459
[TBL] [Abstract][Full Text] [Related]
33. Correlates of survival and the Daumas-Duport grading system for astrocytomas.
Kim TS; Halliday AL; Hedley-Whyte ET; Convery K
J Neurosurg; 1991 Jan; 74(1):27-37. PubMed ID: 1984503
[TBL] [Abstract][Full Text] [Related]
34. Multicentric pleomorphic xanthoastrocytomas: case report.
Haga S; Morioka T; Nishio S; Fukui M
Neurosurgery; 1996 Jun; 38(6):1242-4; discussion 1244-5. PubMed ID: 8727158
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
36. Clinical Features and Surgical Results of Pediatric Pleomorphic Xanthoastrocytoma: Analysis of 17 Cases with a Literature Review.
Wu W; Zuo P; Li C; Gong J
World Neurosurg; 2021 Jul; 151():e778-e785. PubMed ID: 33964500
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
38. Expression of macrophage/histiocytic antigens in pleomorphic xanthoastrocytomas.
Matyja E; Kroh H; Taraszewska A; Nagańska E; Zabek M; Marchel A
Folia Neuropathol; 2003; 41(2):89-95. PubMed ID: 12899201
[TBL] [Abstract][Full Text] [Related]
39. [Immunohistochemical study of proliferation index of astrocytomas classified by new histopathological grading].
Takekawa Y; Sawada T; Sakurai I
Rinsho Byori; 1995 May; 43(5):483-6. PubMed ID: 7783368
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological study of pleomorphic xanthoastrocytoma: correlation between histological features and prognosis.
Sugita Y; Shigemori M; Okamoto K; Morimatsu M; Arakawa M; Nakayama K
Pathol Int; 2000 Sep; 50(9):703-8. PubMed ID: 11012983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
